A D Darwish1, A M Helal2, N H Aly El-Din3, L L Solaiman4, A Amin5. 1. Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt. Electronic address: amiradd@yahoo.com. 2. Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt. 3. Biostatistics & Epidemiology, National Cancer Institute, Cairo University, Cairo, Egypt. 4. Medical Oncology, Beni Suef University, Egypt. 5. Radiation Oncology and Nuclear Medicine, National Cancer Institute, Cairo University, Cairo, Egypt.
Abstract
OBJECTIVE: The aim is to identify the epidemiological and clinicopathological features associated with young breast cancer (BC) patients and to discuss factors affecting tumor recurrence and DFS. PATIENTS & METHODS: A retrospective analysis was conducted based on medical records from young females patients aged ≤35 years with pathologically confirmed primary breast cancer treated during 2008-2010 at NCI. Cases with non invasive cancer and non carcinoma histology are excluded. RESULTS: Of the 5408 cases diagnosed with breast cancer, 554 were young. Four hundred & fifty eight patients representing 9.2% were within our inclusion criteria. Almost half of the patients (45.9%) presented with stage III. Axillary nodes involvement was in 63.9%, 83.3% were grade 2. More than one quarter of tumors was hormone receptors negative (28.8%) & Her2 was over-expressed in 30%. Mastectomy was offered in 72% while conservative breast surgery in 26%, 69.2% received chemotherapy either adjuvant, neoadjuvant or both, 82.5% received adjuvant radiotherapy, 68.6% received hormonal therapy. Metastatic disease developed in 51.3%, with 31% having more than one site of metastases. After a median follow up period of 66 months, the median DFS of patients was 60 months. The median DFS was significantly shorter among patients with positive lymph nodes (P < 0.0001), ER negative disease (P = 0.045) and stage III disease (P < 0.0001). CONCLUSION: Breast cancer in young women is aggressive from the time of diagnosis. Our results provide baseline data of young BC in the Middle East & North Africa region; thus, contributing to future epidemiological and hospital-based researches.
OBJECTIVE: The aim is to identify the epidemiological and clinicopathological features associated with young breast cancer (BC) patients and to discuss factors affecting tumor recurrence and DFS. PATIENTS & METHODS: A retrospective analysis was conducted based on medical records from young females patients aged ≤35 years with pathologically confirmed primary breast cancer treated during 2008-2010 at NCI. Cases with non invasive cancer and non carcinoma histology are excluded. RESULTS: Of the 5408 cases diagnosed with breast cancer, 554 were young. Four hundred & fifty eight patients representing 9.2% were within our inclusion criteria. Almost half of the patients (45.9%) presented with stage III. Axillary nodes involvement was in 63.9%, 83.3% were grade 2. More than one quarter of tumors was hormone receptors negative (28.8%) & Her2 was over-expressed in 30%. Mastectomy was offered in 72% while conservative breast surgery in 26%, 69.2% received chemotherapy either adjuvant, neoadjuvant or both, 82.5% received adjuvant radiotherapy, 68.6% received hormonal therapy. Metastatic disease developed in 51.3%, with 31% having more than one site of metastases. After a median follow up period of 66 months, the median DFS of patients was 60 months. The median DFS was significantly shorter among patients with positive lymph nodes (P < 0.0001), ER negative disease (P = 0.045) and stage III disease (P < 0.0001). CONCLUSION:Breast cancer in young women is aggressive from the time of diagnosis. Our results provide baseline data of young BC in the Middle East & North Africa region; thus, contributing to future epidemiological and hospital-based researches.
Authors: Sara Ahmed Aglan; Ahmad Mohamad Zaki; Amel Sobhy El Sedfy; Heba Gaber El-Sheredy; Ola Hussein Elgaddar Journal: Rep Biochem Mol Biol Date: 2022-04
Authors: Cynthia Villarreal-Garza; Alejandra Platas; Melina Miaja; Alan Fonseca; Fernanda Mesa-Chavez; Marisol Garcia-Garcia; Judy-Anne Chapman; Edna A Lopez-Martinez; Claudia Pineda; Alejandro Mohar; Carmen L Galvez-Hernandez; Andrea Castro-Sanchez; Bertha-Alejandra Martinez-Cannon; Regina Barragan-Carrillo; Jose F Muñoz-Lozano; Paul Goss; Juan E Bargallo-Rocha; Dione Aguilar; Servando Cardona; Mauricio Canavati Journal: JCO Glob Oncol Date: 2020-03